

2018 Ischaemic Heart Disorders Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Ischaemic Heart Disorders Market

<https://marketpublishers.com/r/280D1F7E465EN.html>

Date: June 2018

Pages: 70

Price: US\$ 999.00 (Single User License)

ID: 280D1F7E465EN

Abstracts

Ischaemic heart disorder is a heart condition in which plaque piles up in arteries of a patient, which reduces the area for free flow of blood, thereby, causing angina or chest pain. This can eventually turn out to be a heart attack and arrhythmia. With an estimated 18 million population being affected in the US, Ischaemic heart disorders are among the most rapidly expanding disease in the US and world. Further, the US Ischaemic heart disorders market is sized at \$95 billion during 2017.

To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Ischaemic Heart Disorders pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Ischaemic Heart Disorders pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Ischaemic Heart Disorders pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of LIST OF FIGURES

1.2 List of Tables

2 ISCHAEMIC HEART DISORDERS PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview

2.2 Ischaemic Heart Disorders Pipeline Snapshot

2.3 Ischaemic Heart Disorders Pipeline by Phase

2.4 Ischaemic Heart Disorders Pipeline by Company

2.5 Ischaemic Heart Disorders Pipeline by Mechanism of Action

3 ISCHAEMIC HEART DISORDERS- COMPANY WISE PIPELINE ANALYSIS

advanceCor GmbH

Angionetics Inc

AngioSoma Inc

APT Therapeutics Inc

Ascendia Pharmaceuticals LLC

AstraZeneca Plc

Bayer HealthCare Pharmaceuticals

Bio-Thera Solutions Ltd

Biscayne Pharmaceuticals Inc

Bracco Imaging S.p.A.

Capricor Therapeutics Inc

CardioVascular BioTherapeutics Inc

CSL Ltd

DalCor Pharmaceuticals Inc

Hemostemix Inc

Idorsia Ltd

Jaan Biotherapeutics LLC

LipimetiX Development Inc

MedImmune LLC

Pharmahungary

Proteon Therapeutics Inc

Recardio, Inc.

Resverlogix Corp
Servier Laboratories Limited
The Medicines Company
Vasade Biosciences
VESSL Therapeutics Ltd
ViroMed Co Ltd
XyloCor Therapeutics Inc
List Continues...

4 ISCHAEMIC HEART DISORDERS R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN ISCHAEMIC HEART DISORDERS PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Ischaemic Heart Disorders Pipeline by Phase, H2- 2018

Figure 2: Ischaemic Heart Disorders Pipeline by Companies, H2- 2018

Figure 3: Company Wise Pipeline Drug Phases, H2- 2018

Figure 4: Ischaemic Heart Disorders Pipeline by Mechanism of Action, H2- 2018

Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018

List Of Tables

LIST OF TABLES

Ischaemic Heart Disorders Pipeline by Phase, H2- 2018

Ischaemic Heart Disorders Pipeline by Companies, H2- 2018

Ischaemic Heart Disorders Pipeline by Mechanism of Action, H2- 2018

Table 1: advanceCor GmbH Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 2: Angionetics Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 3: AngioSoma Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 4: APT Therapeutics Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 5: Ascendia Pharmaceuticals LLC Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 6: AstraZeneca Plc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 7: Bayer HealthCare Pharmaceuticals Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 8: Bio-Thera Solutions Ltd Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 9: Biscayne Pharmaceuticals Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 10: Bracco Imaging S.p.A. Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 11: Capricor Therapeutics Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 12: CardioVascular BioTherapeutics Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 13: CSL Ltd Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 14: DalCor Pharmaceuticals Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 15: Hemostemix Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 16: Idorsia Ltd Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 17: Jaan Biotherapeutics LLC Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 18: LipimetiX Development Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 19: MedImmune LLC Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 20: Pharmahungary Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 21: Proteon Therapeutics Inc Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 22: Recardio, Inc. Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 23: Resverlogix Corp Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 24: Servier Laboratories Limited Ischaemic Heart Disorders Pipeline Drugs, H2-2018

Table 25: The Medicines Company Ischaemic Heart Disorders Pipeline Drugs, H2-2018

Table 26: Vasade Biosciences Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 27: VESSL Therapeutics Ltd Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 28: ViroMed Co Ltd Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

Table 29: XyloCor Therapeutics Inc Ischaemic Heart Disorders Pipeline Drugs, H2-2018

Table 30: List Continues... Ischaemic Heart Disorders Pipeline Drugs, H2- 2018

I would like to order

Product name: 2018 Ischaemic Heart Disorders Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Ischaemic Heart Disorders Market

Product link: <https://marketpublishers.com/r/280D1F7E465EN.html>

Price: US\$ 999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/280D1F7E465EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970